Tokorozawa, Japan

Shigenori Segami

This inventor holds 3 USPTO granted patents. Top assignee: Agro-Kanesho Co., Ltd.. Active years: 1992-2001.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shigenori Segami. Retrieved from https://idiyas.com/inventor/shigenori-segami

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 4.8

ph-index = 2

Forward Citations = 25(Granted Patents)


Company Filing History:


Years Active: 1992-2001

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Biography of Shigenori Segami

Introduction: Shigenori Segami is a notable inventor based in Tokorozawa, Japan. He has made significant contributions to the field of insecticides, holding a total of three patents. His work focuses on developing innovative compounds that enhance the effectiveness of pest control while minimizing toxicity to non-target organisms.

Latest Patents: Among his latest patents are the hexahydrotriazine compounds and insecticides. One of his notable inventions is a hexahydrotriazine compound, specifically 1-(2-chloro-5-pyridylmethyl)-3,5-dimethyl-2-nitroiminohexahydro-1,3,5-triazine. Another is 1-(2-chloro-5-thiazolylmethyl)-3,5-dimethyl-2-nitroiminiohexahydro-1,3,5-triazine, which also serves as an effective insecticide. Additionally, he has developed nitroguanidine compounds that are useful as insecticides, which are designed to be highly effective against harmful insects while being low in toxicity to warm-blooded animals, fish, and crustaceans.

Career Highlights: Shigenori Segami has dedicated his career to advancing the field of agricultural chemistry. His innovative approaches to insecticide formulation have garnered attention and respect within the scientific

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…